IMSRESEARCH (IMS LifeCycle, R&D Focus)
Subject
Coverage• All phases of drug development worldwide• Biotechnological products• New formulations

File Type

Substance

Features

Thesaurus

None

Alerts (SDIs)

Not available

CAS Registry
Number® IdentifiersPage Images

Keep & Share




SLART




Learning Database

Structures

RecordContent• Substance information• CAS Registry Number and Chemical
Name• Structures• Pharmacology

File Size

49,767 records (01/2023)

Coverage

1977-present

Updates

Static File

Language

English

Database
Producer

IQVIA
210 Pentonville Road
London N1 9JY
United Kingdom
Phone: (+44) 020 3075 5888
Email: info@uk.imshealth.com
Web: http://www.imshealth.com

STN Easy®

• Development and licensing statusworldwide• Scientific and commercial summaries• Abstracts of significant scientific papers-

January 2023

2
IMSRESEARCH-_

Sources

Information is gathered from direct reports from companies on their research anddevelopment, conferences, patent and journal literature, and attendance at symposia on
medical, clinical, and research subjects.

User Aids• Anatomical Therapeutic Classification Codes (available from the producer)• Online Helps (HELP DIRECTORY lists all help messages available)• STNGUIDE

Clusters• BIOSCIENCE• CASRNS• PHARMACOLOGYSTN Database Clusters Information.

PricingEnter HELP COST at an arrow prompt (=>).

January 2023

3
IMSRESEARCH

Search and Display Field Codes
Fields that allow left truncation (/BI, /CNS) are indicated by an asterisk (*).
Search Field Name

SearchCode

Display
Codes

Search Examples

Basic Index* (contains single
words from text (TX), chemicalname (CN), classification code(CC), controlled term (CT),revision note (RNTE), reference(RE), latest information (LI),company name (CO), patentassignee (PA), development
status (DSTA), geographic terms(GT), launch country (LNC)
fields, as well as CAS Registry
Numbers)None(or /BI)S BETA BLOCKER#S JANSSEN
S JAPAN (L) REGISTERED
S 61337-67-5
S ?CLASS?

CC, CN, CO,
CT, DSTA, LI,
LNC, RE, RN,
RNTE, TX

Accession Number

/AN

AN

Availability for Licensing
Chemical Name (contains
chemical name, generic name,reference, laboratory code, andtrade name)Chemical Name Segment *Classification Code (1,2)(code and text)

/AV
/CN

S 93:234/AN
S 1998:234/AN
S WORLDWIDE/AV
S NEBIVOLOL/CN

CN, TNCC

Company Name (contains
companies, originators,
licensees, licensors, patentassignees, corporations,
nationality, and region) (1)Controlled Term (contains
indication and pharmacology(action))Development Status (contains
status, stage, region, andindication)
Entry Date (3)Field Availability(code and text)
Geographic Term(country name and ISO code)
Highest Development Phase
Journal Title (4)Not Available for Licensing
Patent Assignee (1)/CO

S ?METHYLENE?/CNS
S CNS DRUGS/CCS C7A/CC
S C/CCS (LICENSEE(L)BERLEX)/COS HOECHST ROUSSEL/CO/CT

S MULTIPLE SCLEROSIS/CTS BIOTECHNOLOGY/CT

CT

/DSTA

S (REGISTERED (L) UNITED STATES)/DSTAS (PHASE III (L) ALZHEIMER DISEASE)/DSTA

DSTA

/ED
/FA

S L1 AND ED>20010100
S RN/FAS PATENT ASSIGNEE/FA
S UK/GTED
FA

DSTA, HDP
JT, SO
DSTA
CO

Publication Date (3)/PD

Publication Year (3)Reference(code and text)

/PY
/RE

S PRECLINICAL/HDPS R&D FOCUS/JTS JAPAN/NAVS AMGEN/PAS KIRIN AMGEN/PAS FEB 23, 1998/PD
S 19980223/PD
S PY>=1997
S PINN/RE
S BAN/RE

/CNS
/CC

/GT
/HDP
/JT
/NAV
/PA

DSTA
CN, RE, TN

CO

CO, DSTA

PD, SOPY, SORE

January 2023

4
IMSRESEARCH

Search and Display Field Codes (cont'd)
SearchCode

Search Field Name
Revision Date (3)/RDAT

Revision Note
Source (contains journal title andpublication date) (4)Stage (3)

/RNTE
/SO

StatusTrade Name
Update Date (3)

/STA
/TN
/UP

/STG

Display
Codes

Search Examples
S RDAT>=JAN 2001
S 19980600/RDAT
S LICENS?/RNTE
S (R&D FOCUS AND 2001)/SO

RDAT

S 20/STG
S STG>30
S NEW DRUG/STAS BETASERON/TN
S L7 AND UP>=20010100

DSTA, HDP

RNTE
SO

STA
CN, TNUP(1) Search with implied (S) proximity is available in this field.
(2) For details on the IMSRESEARCH Classification Codes, enter HELP CLASSCODES at an arrow prompt (=>) in the file.
(3) Numeric search field that may be searched with numeric operators or ranges.
(4) The source for all records is R&D Focus.

Limiting Search Codes
Only an L-number for an answer set created in DRUGUPDATES may be limited.
Search Field Name
Available for licensing
New drugs
Unavailable for licensing

SearchCode/LICENSE/NEW/NLICENSE

Search Examples
S L1/LIC,NEW (1,2)
S L1/NEWS L1/NLI (1)(1) The code may be abbreviated to the first three letters.
(2) An answer set may be limited to more than one subject area.

DISPLAY and PRINT Formats
Any combination of formats may be used to display or print answers. Multiple codes must be separated by
spaces or commas, e.g., D L1 1-5 CN CO. The fields are displayed or printed in the order requested.
Hit-term highlighting is available in all fields except DSTA, CO, FA, GT, HDG, PY, STR, STS, and STF.
Highlighting must be on during SEARCH to use the HIT, KWIC, and OCC display formats.
FormatAN (1)CCCT
ED (UP)FA (1,2)
HDP (STG)
JT (1,2)
LI
PD (1,2)
PY (1,2)
RDAT (RNTE)
RE (1)RN
SO (1)

January 2023

Content
Accession Number
Classification CodeControlled Term (Indication and Pharmacology)
Entry Date (Update Date)
Field Availability
Highest Development Phase and Stage
Journal Title
Latest Information
Publication Date
Publication Year
Revision Date and Revision Note
Reference
CAS Registry Number and CAS Registry Numbers for Derivatives
SourceExamplesD L1 3 AN
D CC 1,3-5
D CT
D ED
D L1 FA 3
D HDP
D 1,3,6,8 JT L5
D LI
D L8 PD 1-3
D 1,4 PY
D RDAT
D RE
D L1 RN
D SO

5IMSRESEARCHDISPLAY and PRINT Formats (cont'd)FormatContent

ExamplesSTA (1)STF
STR (3)
STS (3)TN
TX

Status
Structure (No stereo bonds)
Structure (Stereo bonds and R/S/E/Z labels, when available)
Structure (Stereo bonds, when available
Trade Name
Text (Patent Summary, Commercial Summary, Scientific Summary)

D STA L1 4
D STF 3,4
D STR
D STS
D L3 TND TX 2 L5

ALL (3)

AN, SO, DN, STA, CN (Generic Name), RE, CN (Laboratory Name), CN(Trade Name), CN (Chemical Name) RN, STR, RN (Derivatives), CC,
CT, HDP, ED, LI, DSTA, CO, TX, RDAT, RNTE
Chemical Names (Generic Name, Reference, Laboratory Name, TradeName, and Chemical Name)
Tabular display of Company Information (Type, Company, Nationality,
Corporation, Region) and Licensing Contact
Tabular display of Development Status (Type, Status, Stage, Region,
Indication)
DSTA, COALL, indented with text labels
AN, SO, STA, CN (Generic Name), RE, CN (Laboratory Name), CN(Trade Name), CN (Chemical Name), RN, STR, RN (Derivatives), CC,
HDP, ED, CO (Default format)
IDE, indented with text labels (IIDE is the default)
STD, indented with text labels
Tabular display of Patent Assignee information (Type, Company,
Nationality, Corporation, Region)
CN (Generic Name) (random display without answer number)
AN, SO, STA, CN (Generic Name), RE, CN (Laboratory Name), CN(Trade Name), CN (Chemical Name), RN, STR, RN (Derivatives), CC,
CT, HDP, ED, LI, DSTA, CO, TX
CN (Generic Name)
Table containing the answer number, Class, Compound (Generic Name),
Highest Phase, and Originator for a single answer or several records ina single table
Table containing the answer number, Company, Compound (GenericName), Class, Highest Phase, and Type for a single answer or several
records in a single table
Table containing the answer number, RN, Compound (first GenericName, first Laboratory Name, and first Trade Name), and Class for asingle answer or several records in a single table

D ALL 2

Fields containing hit terms
Hit terms plus 20 words on either side (KeyWord-In-Context)
Number of occurrences of hit terms and fields in which they display

D HIT
D KWICD OCC 1-6

CN
CO
DSTA (AV, NAV)GT
IALL (3)IDE (3)

IIDE (3)
ISTD (3)PA (2)
SCAN (1,4)
STD (3)

TRIAL (SAM) (1)
CCTAB

COTAB

IDETABHIT
KWIC
OCC (1)

D 1-3,7,8 CN
D CO
D DSTAD GT
D IALL
D IDE

D L3 2 IIDED ISTDD PA
D L2 SCAN
D STD

D SAM 1-10
D L3 4-10 CCTABD COTAB 1-10

D L4 IDETAB 1-3(1) No online display fee for this format.
(2) Custom display format only.
(3) Stereo structure diagrams are available only on graphics terminals and in offline prints.
(4) SCAN must be specified on the command line, i.e., D SCAN or DISPLAY SCAN.

January 2023

6
IMSRESEARCHSELECT, ANALYZE, and SORT Fields
The SELECT command is used to create E-numbers containing terms taken from the specified field in ananswer set.
The ANALYZE command is used to create an L-number containing terms taken from the specified field in ananswer set.
The SORT command is used to rearrange the search results in either alphabetic or numeric order of thespecified field(s).
Field Name
Accession Number
Availability for Licensing
CAS Registry Number
CAS Registry Number and Chemical Names
Chemical NameClassification CodeCompany NameControlled Term
Development Status
Entry Date
Geographic Term
Highest Development Phase
Journal Title
Latest Information
Not Available for Licensing
Occurrence Count of Hit Terms
Originator
Patent Assignee
Publication Date
Publication Year
Revision Date
Revision NoteStage
StatusTrade Name
Text
Update Date

Field CodeANALYZE/
SELECT (1)

SORT

AN
AV
RN
CHEM
CN
NAME
CC
CO
CT
DSTA
ED
GT
HDP
JT
LI
NAV
OCC
ORIGINATOR
PA
PD
PY
RDAT
RNTE
STG
STA
TN
TX
UP

Y
Y (3)
Y (4)
Y (5)
Y (6)
Y (7)
Y
Y
Y
Y (3,8)
Y
Y
Y (3)
Y
Y (2)
Y (3)
N
N
Y (3)
Y
Y (3)
Y
Y
Y (3)
Y
Y
Y (2)
Y

N
N
Y
N
Y
N
N
Y
N
N
Y
N
Y
Y
N
N
Y
Y
Y
Y
Y
Y
N
Y
N
Y
N
Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HITCT.
(2) Appends /BI to the terms created by SELECT.
(3) SELECT HIT and ANALYZE HIT are not valid with this field.
(4) Selects or analyzes the CAS Registry Numbers for the substance and any derivatives in the record with /BI appended to the terms
created by SELECT.
(5) Selects or analyzes the generic names, laboratory names, trades names, chemical name, and CAS Registry Numbers for thesubstance and any derivatives in the record with /BI appended to the terms created by SELECT.
(6) Selects or analyzes the generic names, reference, laboratory names, trades names, and chemical name.
(7) Selects or analyzes the generic names, laboratory names, trades names, and chemical name with /BI appended to the terms createdby SELECT.
(8) Selects or analyzes the status, region, and indication.

January 2023

7
IMSRESEARCH

Sample Records
DISPLAY IALLACCESSION NUMBER:
2010:357 IMSRESEARCH
SOURCE:R&D Focus, (04 Mar 2010)
DOCUMENT NUMBER:
2500677
STATUS:NEW DRUG
LABORATORY NAME:
ABT 072
STRUCTURE:
STRUCTURE DIAGRAM IS NOT AVAILABLE
CLASSIFICATION:
J5B1 Viral Hepatitis Products
INDICATION:
hepatitis C
ACTION:RNA polymerase inhibitor
ADMINISTRATION:
oral
HIGHEST DEV. PHASE: Phase II (40)
ENTRY DATE:Entered STN: 8 Mar 2010
Last Updated on STN: 6 Apr 2010
LATEST INFORMATION: 04 March 2010 : Abbott and Enanta announced on 2 March2010 the initiation of a phase II trial of ABT 450, ABT 333
and ABT 072 in treatment-naive patients with hepatitis C
virus (HCV) genotype 1 infection. ABT 450, a proteaseinhibitor developed by Abbott and Enanta, and ABT 333 andABT 072, two non-nucleoside polymerase inhibitors developed
exclusively by Abbott, will be dosed individually in
combination with standard of care (SOC). The study will
evaluate the safety, tolerability, pharmacokinetics andantiviral activity of the agents. After a three-day
monotherapy period, each antiviral agent will beadministered with pegIFN and ribavarin (SOC) for 12 weeks,
followed by SOC alone for an additional 36 weeks.
CURRENT DEVELOPMENT STATUS:
Type | Status |Stage|
Region|Indication=======+========+=====+=============+===========
Highest|Phase II|40||
Phase ||||-------+--------+-----+-------------+----------Phase |Phase II|40|United States|hepatitis C

COMPANY INFORMATION:
Type|Company|Nationality| Corporation==========+=======+===========+==============
Originator|Abbott |USA
|Abbott (United|||States)

COMMERCIAL SUMMARY:
Commercial overview. Overview
Abbott is developing ABT 072, a non-nucleoside polymerase inhibitor, for thetreatment of hepatitis C virus (HCV) infection. A phase II trial of the agent
initiated in February 2010 in patients with HCV genotype 1 infection.
R&D progress. **Hepatitis C**
Phase II, Abbott, USA.---DESIGN:Trial started - Feb 2010. A randomized,
double-blind, parallel assignment phase II trial of ABT 450, ABT 333 and ABT
072 has been initiated in treatment-naive patients with hepatitis C virus (HCV)
genotype 1 infection. The agents will be dosed individually in combination withstandard of care (SOC). The study will evaluate the safety, tolerability,
pharmcokinetics and antiviral activity of the agents. After a three-day
monotherapy period, each antiviral agent will be administered with pegIFN andribavarin (SOC) for 12 weeks, followed by SOC alone for an additional 36 weeks.
The study's primary endpoint will be maximum decrease from baseline in log10
HCV RNA levels during treatment with the agents as monotherapy. Secondary
endpoints include the assessment of patients with RVR (HCV RNA level less than
25 IU/mL), as well as partial EVR (HCV RNA decrease more than 2 log10 IU/mL) or
complete EVR (HCV RNA level less than 25 IU/mL) (Abbott, MAR 2010;
ClinicalTrials.gov, FEB 2010).
Phase I, Abbott, USA.---DESIGN:Trial started - Sep 2009. A randomized,
placebo-controlled phase I trial of single and multiple doses of ABT 072 hasbeen conducted in the USA in approximately 52 healthy volunteers(ClinicalTrials.gov, FEB 2010).
Phase I, Abbott, USA.---DESIGN:Trial started - Jul 2009. An open-label,randomized phase I trial has been conducted to evaluate the bioavailability of
two ABT 072 tablet formulations compared with ABT 072 capsule formulation inapproximately 18 healthy volunteers (ClinicalTrials.gov, AUG 2009).
Phase I, Abbott, USA.---DESIGN:Trial started - Apr 2009. A randomized,
double-blind phase I trial of ABT 072 has been conducted in approximately 32
healthy volunteers. Safety, tolerability and pharmacokinetics of multiple dosesof ABT 072 have been assessed (ClinicalTrials.gov, JUL 2009).
Phase I, Abbott, USA.---DESIGN:Trial started - Sep 2008. A randomized,
double-blind phase I trial to evaluate the safety, tolerability andpharmacokinetics of ABT 072 has been conducted in approximately 100 healthy
volunteers and HCV genotype 1 infected patients (ClinicalTrials.gov, MAY 2009).

January 2023

8
IMSRESEARCHDEVELOPMENT HISTORY:FEB 2010
Abbott trial started (Phase II), USA (hepatitis C) .
SEP 2008
Abbott trial started (Phase I), USA (hepatitis C) .

D IIDEACCESSION NUMBER:
2010:517 IMSRESEARCH
SOURCE:R&D Focus, (08 Apr 2010)
DOCUMENT NUMBER:
2500831STATUS:NEW DRUG
GENERIC NAME:
tuberculosis therapy, MicuRx/Cumencor/Pfizer
STRUCTURE:
STRUCTURE DIAGRAM IS NOT AVAILABLE
CLASSIFICATION:
J4A Antitubercular Products
HIGHEST DEV. PHASE: Discovery (10)ENTRY DATE:Entered STN: 9 Apr 2010
Last Updated on STN: 9 Apr 2010
COMPANY INFORMATION:
Type|Company |Nationality| Corporation==========+========+===========+================
Originator|Cumencor|China|Cumencor (China)----------+--------+-----------+---------------Originator|MicuRx |USA
|MicuRx (United|||States)----------+--------+-----------+---------------Originator|Pfizer |USA
|Pfizer (United|||States)

In North America

In EMEAIn Japan

CAS Customer Center
P.O. Box 3012
Columbus, Ohio 43210-0012
U.S.A.

CAS Customer Center EMEA
(represented by FIZ Karlsruhe)
P.O. Box 2465
76012 Karlsruhe
Germany

JAICI (Japan Association forInternational Chemical Information)
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021
Japan

Phone:

800-753-4227 (North America)
614-447-3731 (worldwide)
Email:
help@cas.org
Internet: www.cas.org

January 2023

Phone: +49-7247-808-555
E-mail: EMEAhelp@cas.org

Phone:+81-3-5978-3601 (Technical Service)+81-3-5978-3621 (Customer Service)
Email:
support@jaici.or.jp (Technical Service)customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp